Gufic Biosciences surges on receiving patent by EAPO

01 Dec 2020 Evaluate

Gufic Biosciences is currently trading at Rs. 119.55, up by 2.75 points or 2.35% from its previous closing of Rs. 116.80 on the BSE.

The scrip opened at Rs. 120.95 and has touched a high and low of Rs. 121.90 and Rs. 116.00 respectively. So far 42698 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 129.60 on 13-Nov-2020 and a 52 week low of Rs. 37.55 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 121.90 and Rs. 110.10 respectively. The current market cap of the company is Rs. 930.46 crore.

The promoters holding in the company stood at 65.75%, while Institutions and Non-Institutions held 8.79% and 25.46% respectively.

Gufic Biosciences has been granted patent by the Eurasian Patent office (EAPO) for its invention of ‘A Freeze Dried Parenteral Composition of Tigecycline and Process for Preparation Thereof’. Tigecycline is a tetracycline antibiotic medication used for a number of bacterial infections and is used to treat certain serious infections including community acquired pneumonia (a lung infection that developed in a person who was not in the hospital), skin infections, and infections of the abdomen.

Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.

Gufic Biosciences Share Price

321.00 5.75 (1.82%)
25-Apr-2024 14:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1515.15
Dr. Reddys Lab 6200.00
Cipla 1406.35
Zydus Lifesciences 949.00
Lupin 1595.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.